CYCC is a prime takeover target with its pipeline, zero debt, and $19M cash on hand
CYCC is a prime takeover target with its pipeline, zero debt, and $19M cash on hand. I’d expect a "minimum" offer of $150M, which would be roughly $4.20 per share," says Jeremy Richards.
Current target for CYCC.
Roth Capital Buy 7.00
Merriman Buy 7.50
Piper Jaffray Buy 5.00
Cantor Fitzgerald Buy 9.00
Collins Stewart Buy 13.00
Needham & Co Buy 7.00
Lazard Capital Buy 11.00
Partnership Announcement on Sapacatibine – Such an announcement would give any remaining skeptics the knowledge that large pharma has recognized and is investing in CYCC’s accomplishments. The upfront payment would likely be in excess of CYCC’s current market cap ($53 million) and the ongoing royalty stream could be multiples of the current market cap.
Buyout Offer- Some owners of convertible preferred have moved to elect two new board members.These will be two additional board members, not replacement members. I suspect that the board members selected, given the support of the convertible preferred owners, would be more amenable to selling the company than the current board. As mentioned previously, most AML candidates have failed, and many companies are hungry for the lead in a $2 billion market. CYCC is a prime takeover target with its pipeline, zero debt, and $19M cash on hand. I’d expect a minimum offer of $150M, which would be roughly $4.20 per share.
The study is being conducted under a Special Protocol Assessment (SPA) agreement that Cyclacel reached with the U.S. Food and Drug Administration (FDA). SEAMLESS builds on promising 1-year survival observed in elderly patients aged 70 years or older with newly diagnosed AML or AML in first relapse enrolled in a Phase 2 study of single agent sapacitabine.
"The opening of the SEAMLESS study for patient enrollment marks an important milestone for Cyclacel as this is the first pivotal Phase 3 trial ever conducted by the Company," said Spiro Rombotis, President and Chief Executive Officer of Cyclacel. "If it reaches the market, sapacitabine will become an important treatment option for many elderly patients who are suffering from this life-threatening disease. We also look forward to interim data from the Phase 2 study of sapacitabine in Non-Small Cell Lung Cancer (NSCLC). Sapacitabine may be one of few cancer drugs with activity against both hematological malignancies and solid tumors."
The FDA agreed upon a Special Protocol Assessment [SPA] for a phase 3 trial of Sapacitabine for AML, which gives CYCC a clear edge over all competitors with AML candidates. Decitabine, sponsored in part by Johnson and Johnson (JNJ), was the only one of few competitors with an SPA, but their drug failed survival endpoints versus the current therapies. This week, Seattle Genetics’ (SGEN) lintuzumab failed to prolong survival. Celgene’s (CELG) Vidaza is in phase 3, but does not have an SPA and is not administered orally, thereby posing greater safety risks along with lower efficacy in elderly patients. Genzyme’s (GENZ) Clolar was rejected by the FDA due to the study design. Clearly their management could have learned a lesson in patience and foresight to agree upon an SPA as did CYCC’s management. So, not only does CYCC have the only orally-administered treatment for AML, they also offer investors great comfort in that the FDA has already agreed on the late-stage clinical trial design. And, most importantly, they have demonstrated markedly prolonged survival rates, the key endpoint in the upcoming trial.